Log in | Register

Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia

Eun Young Choi| Jin Won Huh| Chae-Man Lim| Younsuck Koh| Sung-Han Kim| Sang-Ho Choi| Yang Soo Kim| Mi-Na Kim| Sang-Bum Hong
Original
Volume 37, Issue 4 / April , 2011

Pages 639 - 647

Abstract

Purpose

The objective of this study is to assess the distribution of vancomycin minimum inhibitory concentrations (MICs) in methicillin-resistant Staphylococcus aureus (MRSA) isolates and evaluate the efficacy of vancomycin relative to vancomycin MICs in adult patients with MRSA nosocomial pneumonia.

Methods

This retrospective cohort study involved adults with MRSA nosocomial pneumonia treated with vancomycin. Vancomycin MICs were determined using Etest. Patients with MRSA and vancomycin MICs ≥1.5 μg/mL and those with MRSA and MICs ≤1 μg/mL were placed in the high- and low-MIC group, respectively. The primary outcomes assessed were clinical response and relapse of MRSA pneumonia within 28 days after vancomycin discontinuation. Secondary outcomes included 28-day mortality, in-hospital mortality and length of hospital stay.

Results

Seventy patients met the inclusion criteria. Mean age and mean Acute Physiological and Chronic Health Evaluation (APACHE) II score upon intensive care unit (ICU) admission of these patients were 67.0 years and 25.9, respectively. Thirty-four (48.6%) isolates had high vancomycin MICs, and 36 (51.4%) had low MICs. There were no significant differences in baseline characteristics between the two groups. Early clinical response rates in the low- and high-MIC groups were 63.9% and 35.3%, respectively (p = 0.031). The high-MIC group had an 8% lower final clinical response rate, but this difference was not significant (p = 0.609). The relapse rate within 28 days was significantly higher in the high-MIC group than in the low-MIC group (29.6% versus 6.9%, p = 0.038). On multivariate analysis, infection by high-MIC strains was an independent predictor of early clinical response failure.

Conclusions

About half of the MRSA isolates had high vancomycin MIC. Patients infected with these strains showed slower clinical response and higher relapse rate than patients infected with low vancomycin MIC isolates.

Keywords

References

  1. National Nosocomial Infections Surveillance (NNIS) (2003) System report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 31:481–498
    • View reference on publisher's website
  2. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 32(Suppl 2):S114–S132
    • View reference on publisher's website
    • View reference on PubMed
  3. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903
    • View reference on PubMed
  4. Tverdek FP, Crank CW, Segreti J (2008) Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin 24:249–260, vii–viii
  5. Shorr AF, Combes A, Kollef MH, Chastre J (2006) Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34:700–706
    • View reference on publisher's website
    • View reference on PubMed
  6. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS (2005) Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128:1414–1422
    • View reference on publisher's website
    • View reference on PubMed
  7. Sakoulas G, Moellering RC Jr (2008) Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 46(Suppl 5):S360–S367
    • View reference on publisher's website
    • View reference on PubMed
  8. Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C (1993) Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37:281–286
    • View reference on PubMed
  9. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E (1996) Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38:865–869
    • View reference on publisher's website
    • View reference on PubMed
  10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144
    • View reference on publisher's website
    • View reference on PubMed
  11. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200
    • View reference on publisher's website
    • View reference on PubMed
  12. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320
    • View reference on publisher's website
    • View reference on PubMed
  13. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402
    • View reference on publisher's website
    • View reference on PubMed
  14. Moise PA, Sakoulas G, Forrest A, Schentag JJ (2007) Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51:2582–2586
    • View reference on publisher's website
    • View reference on PubMed
  15. Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–2005. J Antimicrob Chemother 60:788–794
    • View reference on publisher's website
    • View reference on PubMed
  16. Pea F, Viale P (2009) Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? J Trauma 67:893–894 author reply 894–895
    • View reference on publisher's website
    • View reference on PubMed
  17. Jung YJ, Koh Y, Hong SB, Chung JW, Ho Choi S, Kim NJ, Kim MN, Choi IS, Han SY, Kim WD, Yun SC, Lim CM Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 38:175–180
  18. Gang RK, Sanyal SC, Mokaddas E, Lari AR (1999) Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns 25:640–644
    • View reference on publisher's website
    • View reference on PubMed
  19. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388–394
  20. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789–1797
    • View reference on publisher's website
    • View reference on PubMed
  21. Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, Leeper KV Jr, Solomkin JS (2008) Early microbiological response to linezolid vs. vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134:1200–1207
    • View reference on publisher's website
    • View reference on PubMed
  22. Domenech A, Ribes S, Cabellos C, Dominguez MA, Montero A, Linares J, Ariza J, Gudiol F (2004) A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microb Drug Resist 10:346–353
    • View reference on publisher's website
    • View reference on PubMed
  23. (2002) Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR Morb Mortal Wkly Rep 51:565–567
  24. Fridkin SK (2001) Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 32:108–115
    • View reference on publisher's website
    • View reference on PubMed
  25. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG Jr (2009) Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 200:1355–1366
    • View reference on publisher's website
    • View reference on PubMed
  26. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G (2005) Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56:519–523
    • View reference on publisher's website
    • View reference on PubMed
  27. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942
    • View reference on publisher's website
    • View reference on PubMed
  28. Mohr JF, Murray BE (2007) Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44:1536–1542
    • View reference on publisher's website
    • View reference on PubMed
  29. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947–955
    • View reference on publisher's website
    • View reference on PubMed
  30. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J (2007) Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med 35:146–154
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement